Join the Tapentadol group to help and get support from people like you.
Tapentadol News
1 in 10 ICU Patients With Heart Issues Has Illicit Drugs in Their System
FRIDAY, Aug. 18, 2023 – More than 1 out of every 10 patients who land in an ICU with a potentially deadly heart emergency test positive for recreational drug use, a new French study reports. About...
Prevalence of Recreational Drug Use 11 Percent in Cardiac ICUs
FRIDAY, Aug. 18, 2023 – For patients hospitalized in intensive cardiac care units (ICCUs), the prevalence of recreational drug use is 11 percent, according to a study published online Aug. 15 in...
Most People Initiating Opioid Rx Have Very Low Use Trajectory
MONDAY, Aug. 14, 2023 – Most adults initiating treatment with prescription opioids have relatively low and time-limited exposure to opioids during a five-year period, according to a study published...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Approves Nucynta ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
RARITAN, N.J., Aug. 29, 2012 /PRNewswire/ – Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for...
Nucynta ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Raritan, N.J., August 26, 2011 /PRNewswire/ — Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Nucynta ER, an oral analgesic taken twice daily, f...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Diabetic Neuropathy, Diabetic Nerve Damage, Pain